Friday, November 15, 2013 – 10:00am Health Subcommittee – 2322 Rayburn House Office Building, Washington DC
Many members of Congress brought up concerns about how FDASIA implementation is affecting Rare Disease Drug Development. Dr. Woodcock, FDA’s Director of the Center for Drug Evaluation & Research (CDER) explained how the rare diseases programs at the FDA have been hindered due to Sequestration.
Join RDLA and 200 rare disease advocates in Washington, DC for Rare Disease Day – Week, February 25th – 27th 2014.
You are invited to join RDLA and 200 rare disease advocates in Washington, DC for Rare Disease Day (Week), February 25 – 28, 2013. Below is an overview of the events.
New Study Release: How Limiting Cost Sharing for Specialty Drugs Would Impact Insurance Premiums
Tuesday, September 10, 2013 • 2:00 pm
2456 Rayburn House Office Building
The National Institute of Neurological Disorders and Stroke (NINDS) at the NIH invites members of nonprofit organizations to the Institute’s 2013 Nonprofit Forum. The Forum provides an opportunity for nonprofit leaders to network with colleagues and to engage in discussions with NINDS staff.
Natcher Conference Center, Bethesda, MD September 10 and 11, 2013
Demystifying FDA: An Exploration of Drug Development
The meeting will serve as a forum for FDA’s patient stakeholders and the general public, including health professionals, academia, and industry to learn about regulatory issues related to drug development, analyze where in the process patient input may be most practical and most valuable, and explore practicable approaches to incorporating meaningful patient input that will represent broad patient perspectives in medical product development and regulatory decision-making.
Advocates September Luncheon & Conference Call
Wednesday, Sept. 11, 2013 12:00 – 1:30 pm Eastern
750 9th Street, NW, Washington, DC 6th floor Office of Akerman Senterfitt – Washington Conference Room
Time: 11:30 a.m. to 3 p.m.: The Research!America National Health Research Forum engages leaders in government, industry, academia, patient advocacy organizations and the media in a dialogue concerning research to improve health and health care. It is a singular event aimed at confronting issues that bear on our nation’s capacity to maintain its global leadership in the medical research arena, and on the health, safety, and prosperity of the American people.